Overview

Price chart · mood · technical indicators

ABVC

ABVC Biopharma Incstock Healthcare

Biotechnology

$1.1932.77%Current Market Mood:Strong Bearish

Market Mood

Price Range (1Y)

$0.90$5.48

Current: $1.19

Idea: EMA

1Y Return

+104.8%

Sharpe 3Y

0.76

Market Comparison

vs Healthcare Sector & Biotechnology Industry

ABVC

-32.77%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-0.390.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$34.1MMicro cap

Valuation

Forward P/E: —
PEG ratio: —
P/B: 3.23
P/S (TTM): 27.42
EV/EBITDA: -1.90

Profitability & growth

ROE (TTM): -87.8%
Operating margin: 0.0%
Revenue growth YoY: 104.5%
Dividend yield: —
Beta: 0.57

Last earnings

Oct 31, 2025 · Estimate $0.00 · Reported $-0.05

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About ABVC Biopharma Inc

Company profile

American BriVision (Holding) Corporation, a clinical-stage biopharmaceutical company, develops drugs and medical devices to meet unmet medical needs in the United States.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 44370 OLD WARM SPRINGS BOULEVARD, FREMONT, CA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$34.1M

Shares outstanding$26.0M

52W high$5.48

52W low$0.88

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

ABVC

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

12 Health Care Stocks Moving In Thursday's Pre-Market Session

ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) — 10-Q Summary

ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit

ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning

ABVC BioPharma Delays Quarterly SEC Filing

ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026

TradingKey

ABVC Options Chain — NASDAQ:ABVC

ABVC Options Volatility — NASDAQ:ABVC

12 Health Care Stocks Moving In Monday's Intraday Session - ABVC BioPharma (NASDAQ:ABVC), Aditxt (NASDAQ

ABVC Stock News Today | Earnings, Events & Price Alerts

ABVC BioPharma Shareholders Back Board, Equity Plan Changes

ABVC BioPharma (ABVC) plans 2026 virtual meeting, director votes and equity plan increase

ABVC SEC Filings - Abvc Biopharma Inc 10-K, 10-Q, 8-K Forms

According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025.

Restatement and asset surge reshape ABVC BioPharma (NASDAQ: ABVC)

ABVC BioPharma (NASDAQ: ABVC) details biotech pipeline, risks and listing

According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025.

According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025.

ABVC BioPharma Reports 2025 Form 10-K

About ABVC Biopharma Inc

Classification

Company profile

ABVC

Market Comparison

ABVC Market Analysis

Overview

ABVC

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

12 Health Care Stocks Moving In Thursday's Pre-Market Session

ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) — 10-Q Summary

ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit

ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning

ABVC BioPharma Delays Quarterly SEC Filing

ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026

TradingKey

ABVC Options Chain — NASDAQ:ABVC

ABVC Options Volatility — NASDAQ:ABVC

12 Health Care Stocks Moving In Monday's Intraday Session - ABVC BioPharma (NASDAQ:ABVC), Aditxt (NASDAQ

ABVC Stock News Today | Earnings, Events & Price Alerts

ABVC BioPharma Shareholders Back Board, Equity Plan Changes

ABVC BioPharma (ABVC) plans 2026 virtual meeting, director votes and equity plan increase

ABVC SEC Filings - Abvc Biopharma Inc 10-K, 10-Q, 8-K Forms

According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025.

Restatement and asset surge reshape ABVC BioPharma (NASDAQ: ABVC)

ABVC BioPharma (NASDAQ: ABVC) details biotech pipeline, risks and listing

According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025.

According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025.

ABVC BioPharma Reports 2025 Form 10-K

About ABVC Biopharma Inc

Classification

Company profile

ABVC

Market Comparison